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Fifty one percent severely dehydrated with Systolic BP ranged 0.0–160.0mmHg, 
median 90.0mmHg. Diastolic BP ranged 0.0-110.0 mmHg, median 60.0mmHg. Total 
fluids given ranged 0.0–13.9 L, median 5.2 L. Only 1.4% had fluid output monitored. 
Lacking health insurance (POR= 2.52, CI0.48-13.25), being referred (POR= 0.05, CI0.01-
0.21), male (POR= 0.82, CI0.32-2.16), single (POR= 0.80, CI0.26-2.46) were associated 
with late hospital presentation COnClusIOns: Instituting routine cholera death 
audits in Ghana is crucial to reducing case fatality as late presentation, inadequacy 
of assessment, rehydration, monitoring and lack of Health Insurance were main 
prevalent factors among deaths in the outbreak.
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ObjeCtIves: Influenza infection can be recorded under number of respiratory diag-
noses when patients visit a GP. In addition, the incidence of influenza and respiratory 
infections are known to be highest in younger and elderly age groups. Our objective 
was to describe the consultation rates for eight respiratory diagnoses across four 
influenza seasons as observed through GP consultations in England. MethOds: 
Data were obtained on 775,000 respiratory related GP consultations, across four 
influenza seasons (2010-2014) from the Clinical Practitioners Research Datalink. 
Eligible patients were registered and had 12 months history with a practice at the 
start of the season. An influenza season was defined as 1 September through to 
13 April of the following year. Practice-level consultation rates for each outcome 
were determined by age (seven groups were defined) and season. A Poisson mixed 
effect model was fitted to analyse age effect with inter-practice and inter-season as 
random effects. 18 to 65 age group was the reference population. Results: Across 
all outcomes, consultation rates for influenza or respiratory illness were highest 
amongst young children, with highest rates observed for the 0 to < 2 age group, fol-
lowed by the 2 to < 4 age group. Focussing on individual diagnoses recorded during 
GP consultations, younger children were particularly at risk for upper respiratory 
tract infection and otitis media. Patients over 65 were found to be more at risk for 
pneumonia and lower respiratory tract infection. Inter-practice variation in diag-
noses rates was dominating inter-season variations for most influenza-related 
diagnoses. Biggest seasonal impact was on consultations for influenza-like-illness, 
which were particularly high during the 2010-2011 season, likely due to the H1N1 
epidemic. COnClusIOns: Our findings confirmed that children and the over 65 
population are most at risk of influenza and respiratory illness, and that incidence 
can reliably be evaluated through analysis of GP consultation rates.
INfeCtIoN – Cost studies
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vACCINe IN fINNIsh home CARe CustomeRs ≥ 50 yeARs wIth uNdeRlyINg 
ChRoNIC medICAl CoNdItIoNs
Mankinen PT1, Soini EJ1, Laine J2, Linna M3, Åhman H2, Martikainen J1
1ESiOR Oy, Kuopio, Finland, 2Pfizer Oy, Helsinki, Finland, 3Aalto University, Espoo, Finland
ObjeCtIves: Hospital-treated pneumonias (HTP) are associated with substantial 
individual and societal burden in adults (≥ 50 years) and elderly. Moreover, adults 
e.g. with vascular, metabolic or respiratory diseases have a 3-6 times higher risk 
of HTP when compared with their healthy controls. Persons at risk are likely to 
benefit most from pneumococcal vaccinations. The 13-valent pneumococcal con-
jugate vaccine (PCV13) has showed to prevent community-acquired pneumonia and 
invasive pneumococcal disease in adults. The objective of this study was to estimate 
the expected 5-year health economic impact of targeted PCV13 compared with no 
vaccination in Finnish home care customers. MethOds: A budget impact model 
was developed to predict the impact of PCV13 vaccination in terms of costs and 
HTP events avoided at the national and municipal level. A dynamic-cohort Markov 
modelling approach and a time horizon of 5 years was used. The baseline number 
of home care customers and HTP events were gathered from Finnish national regis-
tries. The efficacy of PCV13 was estimated based on CAPITA trial. Only direct costs in 
2014 value were considered in the analysis. Results: All 105,572 Finnish home care 
customers are considered to be at moderate or high risk for HTP because of under-
lying chronic medical conditions. Vaccination of these people with PCV13 could 
provide an undiscounted net budget savings of about € 49.2 million compared with 
the current no-vaccination situation over the next 5 years. Among the risk groups 
considered, the largest absolute undiscounted net savings (€ 22.3 million) could be 
obtained by vaccinating people with heart disease, due to its high prevalence in the 
target population. COnClusIOns: In Finland, the direct immunization of home 
care customers with PCV13, is estimated to lead to substantial cost savings in the 
following 5 years after vaccination.
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ObjeCtIves: Chronic HCV is a leading cause of hospitalization and death in popu-
lations coinfected with HIV in Italy. Sofosbuvir (SOF) is a pan-genotypic drug, which 
can be used alone or combined with other agents (e.g.Simeprevir,Daclatasvir, 
Ledipasvir) as oral treatment for HCV, with different price levels. We performed 
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ObjeCtIves: To estimate prevalence of HCV, using data from routine practice in 
Italy MethOds: An observational retrospective cohort based on administrative 
databases (containing data from pharmacy registries, hospital discharges, outpa-
tient specialist services and laboratory tests) from a sample of six Italian LHUs was 
performed. The date of the first record related to HCV (i.e., positive HCV testing 
or medications for HCV) during the study period (July 1st, 2009 - June 31st, 2014) 
was considered as a proxy of diagnosis, and used as the index date. Patients with 
data available for at least 6 months prior to index date were followed up from the 
index date until the first of the end of the study period, date of death, or exiting the 
database Results: Overall, 228,157 health-assisted individuals living in the first 
analysed LHU (Central Italy) were considered as the starting population in the study; 
amongst them, 0.4% patients with HCV were enrolled, 56% male, age 58±16 years. 
The most prevalent genotypes were 1 (51±2%), 2 (24±2%), 3 (19±2%) and 4 (5±1%); 
other genotypes had a rate lower than 5%. In terms of co-infections, 6% patients 
were affected by HIV, 3% by HBV, 2% HCV+HBV+HIV, 26% had cirrhosis and 4% HCC. 
The majority of patients (76%) did not receive an antiviral treatment; compared to 
treated patients, they were more frequently aged > 65 years (44% compared to 14% 
in treated patients), females (46%, vs 40%), under ongoing substance/alcohol abuse 
(7% vs 4%). Moreover, 30% of untreated patients had cirrhosis and 5% HCC. Results 
from other LHUs will be available at ISPOR-EU COnClusIOns: This observational 
study showed that 70% of enrolled HCV patients has genotype 1 and 3, and only 
a small proportion of patients with HCV received antiviral therapy. Future analy-
ses should investigate relationships between patients’ characteristics, therapeutic 
choices and outcomes
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ObjeCtIves: Rotavirus gastroenteritis (RVGE) is the leading cause of severe diarrhea 
in children under 5 years of age. Two rotavirus vaccines are licensed to prevent these 
infections. More than hundred economic evaluations have been published on rota-
virus vaccination since 2006 and their results largely vary. An update of a literature 
view was conducted aiming to assess whether differences in the epidemiologi-
cal data used in European evaluations could explain the differences in the results 
obtained. MethOds: A literature review was conducted to retrieve articles reporting 
the cost-effectiveness of rotavirus vaccination in Europe based on criteria used in 
a previously published review (limited to 2001-2011 studies, this update extended 
the search to May 2015), focusing on epidemiological data. The following annual 
incidence RVGE-related data were extracted from the retrieved articles and grouped 
by countries: community-acquired hospitalisation (CAH), emergency department 
(ED) visits, outpatient visits (including general practitioner or paediatrician) and 
RVGE events (including no medical visits). Variations within countries were also 
calculated as the ratio between the maximum and minimum value. Results: 32 
publications (24 manuscripts and 8 conference abstracts) from 13 European coun-
tries were retrieved. The European average (minimum and maximum reported 
value) annual rates were CAH 0.57% (0.09% Portugal; 1.43% Albania), ED visits 1.13% 
(0.22% Portugal; 2.40% France), outpatient visits 3.11% (0.56% Netherlands; 7.17% 
Romania) and RVGE events 9.05% (5.63% Germany; 20.01% Spain). For the countries 
with multiple publications, rates of CAH and outpatient visits showed large variation 
(CAH: France 2.82; outpatient: Ireland 5.78). RVGE rates were generally consistent 
except for United Kingdom (1.93) and Germany (2.50). For ED visit rates the largest 
variability was observed in France (3.16). COnClusIOns: The RGVE disease bur-
den used as input in economic evaluation varies among the studies in the same 
country and across Europe. This may explain the difference in the cost-effective 
results reported.
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ObjeCtIves: Ghana has documented recurrent Cholera outbreaks (Davies-Teye, 
2014); the worst ever in 2014 had high case, death incidence and yet does not rou-
tinely audit these deaths. Auditing the deaths would improve healthcare quality 
delivered to clients This study aimed at developing standardized Cholera Death 
audit tool, describe the deaths and identify prevalent factors that contributed to 
deaths. MethOds: Standardized cholera death audit tool was developed. Census 
of cholera deaths from June – December 2014 in Greater Accra Region made. Medical 
records, surveillance data of deaths from treatment centers reviewed with the devel-
oped audit tool. Data abstracted included socio-demographic, clinical, patient moni-
toring. Data managed in Epi info7. Descriptive, bivariate analysis made and Prevalent 
Odds Ratio (95% Confidence Interval) determined to identify prevalent factors asso-
ciated with deaths. Results: The region documented 20,199 (Attack rate 432 per 
100,000 populations) cholera cases with 121 deaths (CFR 0.60%). La Nkwantanang-
Madina and Ladade Kotopon were most affected with Attack rates above 600 per 
100,000 populations. Ada East, Ashaiman and LEKMA had case fatalities above 0.9%. 
Ages ranged 1–82 years, mean 41.0 ±17, median 39.0, mode 24.0 years. Males consti-
tuted 65.7% and 90.9% did not have health insurance. Duration of home stay ranged 
0-5days. Nineteen percent were dead on arrival and 20.2% within 4hours of arrival. 
